|
Delayed
Nasdaq
16:40:49 14/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 6.600 USD | -1.35% |
|
-4.76% | -46.08% |
| 08-05 | SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome | CI |
| 07-29 | Scisparc Ltd. Announces Establishment of Scientific Advisory Board | CI |
| Market Cap | 3.83M 3.32M 3.12M 2.84M 5.35M 366M 5.43M 36.69M 14.32M 183M 14.4M 14.09M 611M | P/E 2024 |
-0.33x | P/E 2025 | -0.12x |
|---|---|---|---|---|---|
| Enterprise Value | -390K -338K -317K -289K -544K -37.22M -552K -3.73M -1.46M -18.63M -1.46M -1.43M -62.16M | EV / Sales 2024 |
-551,308x | EV / Sales 2025 | 289,759x |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -1.35% | ||
| 1 week | -4.76% | ||
| Current month | -7.30% | ||
| 1 month | +54.57% | ||
| 3 months | +32.53% | ||
| 6 months | +27.31% | ||
| Current year | -46.08% |
| 1 week | 5.86 |  | 7.06 |
| 1 month | 4.31 | | 11.51 |
| Current year | 2.98 | | 15.79 |
| 1 year | 2.98 | | 80.1 |
| 3 years | 2.98 | | 2,687.56 |
| 5 years | 0.49 | | 41,769.08 |
| 10 years | 0.49 | | 41,769.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Oz Adler
CEO | Chief Executive Officer | 39 | 10/01/2022 |
Amitay Weiss
CEO | Chief Executive Officer | 62 | 21/08/2020 |
Adi Zuloff-Shani
CTO | Chief Tech/Sci/R&D Officer | 56 | 08/02/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Amitay Weiss
CHM | Chairman | 62 | 10/01/2022 |
Itschak Shrem
CHM | Chairman | 79 | 21/09/2025 |
Lior Vider
BRD | Director/Board Member | 50 | 21/08/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.35% | -4.76% | -85.07% | -99.26% | 3.83M | |
| -0.10% | -0.77% | +17.58% | +70.16% | 48.57B | |
| -3.26% | -5.31% | +53.19% | +117.23% | 40.99B | |
| -0.60% | -0.94% | -7.29% | +17.35% | 12.35B | |
| -2.75% | +1.88% | +14.81% | +76.92% | 12.2B | |
| -0.19% | -0.19% | +29.10% | +135.91% | 9.08B | |
| +0.90% | +5.03% | +22.89% | +39.14% | 7.41B | |
| +0.52% | +2.08% | +40.75% | -12.45% | 7.13B | |
| -0.07% | +1.72% | +13.39% | +190.65% | 6.86B | |
| +1.45% | +5.76% | -25.73% | +30.37% | 5.92B | |
| Average | -0.53% | +1.56% | +7.36% | +56.60% | 15.05B | |
| Weighted average by Cap. | -1.07% | +1.13% | +25.17% | +81.65% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 1.31 1.13 1.06 0.97 1.82 124.64 1.85 12.5 4.88 62.39 4.9 4.8 208.14 | 0.86 0.74 0.7 0.63 1.19 81.7 1.21 8.19 3.2 40.9 3.21 3.14 136.42 |
| Net income | -6.28M -5.45M -5.11M -4.66M -8.76M -600M -8.9M -60.12M -23.47M -300M -23.59M -23.08M -1B | -12.18M -10.56M -9.9M -9.02M -16.98M -1.16B -17.25M -117M -45.49M -582M -45.72M -44.73M -1.94B |
| Net Debt | -2.01M -1.74M -1.63M -1.49M -2.8M -192M -2.85M -19.24M -7.51M -96.08M -7.55M -7.39M -320M | -4.22M -3.66M -3.43M -3.13M -5.89M -403M -5.98M -40.42M -15.78M -202M -15.86M -15.52M -673M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/08/26 | $6.600 | -1.35% | 2,302 |
| 13/08/26 | $6.690 | +1.36% | 40,586 |
| 12/08/26 | $6.600 | -3.23% | 715,129 |
| 11/08/26 | $6.820 | +3.18% | 12,558 |
| 10/08/26 | $6.610 | -4.62% | 25,118 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- SPRC Stock
Select your edition
All financial news and data tailored to specific country editions
